Hua Wang

Dr. Hua Wang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LGLei Gao
Lei Gao
YXYan-Jun Xiong
Yan-Jun Xiong
YLYa-Xue Liang
Ya-Xue Liang
PHPeng-Fei Huang
Peng-Fei Huang
SLShuang Liu
Shuang Liu
HWHui-Mei Wu
Hui-Mei Wu
Inflammatory cytokines have crucial roles in the pathogenesis of tuberculosis (TB), and interleukin (IL)-27 and IL-35 have a pro-inflammatory and anti-inflammatory effect on many diseases, including infectious diseases. Therefore, we evaluated the relationship between IL-27 and IL-35 gene polymorphism, expression levels, and pulmonary TB (PTB) susceptibility. Nine single-nucleotide polymorphisms (SNPs) in the IL-27 gene (rs181206, rs153109, and rs17855750) and the IL-35 gene (rs4740, rs428253, rs9807813, rs2243123, rs2243135, and rs568408) were genotyped by the SNPscan technique in 497 patients with PTB and 501 controls. There was no significant difference regarding the genotype and allele frequencies of the above SNPs in the IL-27 and IL-35 genes between patients with PTB and controls. Haplotype analysis showed that the frequency of the GAC haplotype in the IL-35 gene was significantly decreased in patients with PTB when compared to controls (p = 0.036). Stratified analysis suggested that the frequency of the IL-27 rs17855750 GG genotype was significantly increased in patients with PTB with fever. Moreover, the lower frequency of the IL-35 rs568408 GA genotype was associated with drug-induced liver injury in patients with PTB. The IL-35 rs428253 GC genotype, as well as the rs4740 AA genotype and A allele, showed significant relationships with hypoproteinemia in patients with PTB. When compared with controls, the IL-27 level was significantly increased in patients with PTB. Taken together, IL-35 gene variation might contribute to a protective role on the susceptibility to PTB, and IL-27 and IL-35 gene polymorphisms were associated with several clinical manifestations of patients with PTB.

1 August 2024 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
YXYan-Jun Xiong
Yan-Jun Xiong
YXYu Xiao
Yu Xiao
LXLei Xie
Lei Xie
LGLei Gao
Lei Gao
YHYi Han
Yi Han
HWHua Wang
Hua Wang
Background: Linezolid (LZD) is a cornerstone medication in the treatment of drug-resistant tuberculosis (DR-TB). However, it frequently triggers adverse effects such as bone marrow suppression, optic neuropathy, and peripheral neuropathy, all of which can impact treatment outcomes and prognosis. Contezolid (CZD), a novel oxazolidinone antibiotic, exhibits comparable antimicrobial efficacy against Mycobacterium tuberculosis as LZD, but with potentially enhanced safety profiles. Case Presentation: This report presents five cases (Cases 1– 5) of LZD intolerance, wherein CZD served as an effective alternative treatment. In Cases 1– 3, LZD administration resulted in bone marrow suppression, primarily manifested as anemia. Transitioning to CZD therapy led to a rise and stabilization of hemoglobin (HGB) levels in Cases 1– 2, and a return to baseline values in Case 3. In Case 4, CZD treatment alleviated symptoms of LZD-induced peripheral neuritis, although complete resolution was not achieved, hinting at potential irreversibility of this type of peripheral neuropathy. In Case 5, direct CZD anti-TB therapy was initiated for recurrent leukopenia and neutropenia, resulting in no further severe myelosuppression and successful recovery. Conclusion: These case studies suggest that CZD could represent an effective and safe option for anti-TB therapy, especially for patients intolerant to LZD.

7 December 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
QHQian Huang
Qian Huang
CWChao-Cai Wang
Chao-Cai Wang
YLYun-Guang Liu
Yun-Guang Liu
CZChang-Ming Zhao
Chang-Ming Zhao
TZTian-Ping Zhang
Tian-Ping Zhang
HWHua Wang
Hua Wang
The present study was performed to evaluate the association of WNT signaling pathway genes variants with pulmonary tuberculosis (PTB) risk in Chinese Han population. Our study subjects were composed of 452 PTB patients and 465 normal controls, and seventeen SNPs of seven genes in WNT signaling pathway (SFRP1, WNT3A, CTNNB1, WIF-1, DKK-1, LRP5, LRP6) were genotyped by SNPscan technique. We found no significant relationship of SFRP1 rs10088390, rs4736958, rs3242, WNT3A rs752107, rs3121310, CTNNB1 rs2293303, rs1798802, rs4135385, WIF-1 rs1026024, rs3782499, DKK-1 rs2241529, rs1569198, LRP5 rs3736228, rs556442, LRP6 rs2302685, rs11054697, rs10743980 polymorphisms with PTB susceptibility. While, WIF-1 rs3782499 variant was associated with susceptibility to PTB under recessive model, and haplotype analysis showed that DKK-1 GA haplotype frequency was significantly increased in PTB patients. The WNT3A rs3121310, CTNNB1 rs2293303 polymorphisms were respectively associated with drug-induced liver injury (DILI), sputum smear-positive in PTB patients. The rs3782499 in WIF-1 gene was related to fever, leukopenia, and the rs1569198 in DKK-1 was linked to sputum smear-positive in PTB patients. In LRP5 gene, rs3736228, rs556442 variants respectively affected the occurrence of DILI, fever, and LRP6 gene rs2302685, rs10743980 variants respectively influenced the development of hypoproteinemia, sputum smear-positive in PTB patients. Our results revealed that WNT signaling pathway genes variation were not associated with the susceptibility to PTB, while WNT3A, CTNNB1, WIF-1, DKK-1, LRP5, LRP6 genetic variations might be closely related to the occurrence of several clinical characteristics of PTB patients.

18 December 2025 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PDF file
QXQing Xia
Qing Xia
AWAnbang Wang
Anbang Wang
YZYan Zhang
Yan Zhang
JMJing Meng
Jing Meng
SWShasha Wu
Shasha Wu
XLXueying Liu
Xueying Liu
Purpose: This study aimed to comprehensively assess the impact of nutritional status and inflammatory response on the severity of pulmonary tuberculosis (PTB). Methods: Hospitalized patients with active PTB were included. Severe PTB was defined as active PTB with ≥3 infected lobes on chest imaging. Nutritional status was determined by the geriatric nutritional risk index (GNRI) and prognostic nutritional index (PNI). Inflammatory markers included monocyte-to-lymphocyte ratio (MLR), neutrophil-to-lymphocyte ratio (NLR), and systemic inflammatory response index (SII). Multivariate logistic regression, receiver operating characteristic (ROC) curves, random forest, and mediation analysis were leveraged to clarify the links of nutritional status and inflammatory response with PTB severity. Results: 337 patients were included. In the fully-adjusted logistic regression model, GNRI (OR: 0.93; 95%CI: 0.90-0.96, P<0.001) and PNI (OR: 0.90; 95%CI; 0.86-0.95, P<0.001) were independent protective factors for severe PTB, whereas NLR (OR: 1.07; 95%CI: 1.01-1.16, P<0.05) and MLR (OR: 3.11; 95%CI: 1.16-9.71, P0.05). GNRI mediated 51.64% and 60.58% of the effect of NLR and MLR on PTB, respectively. PNI mediated 70.15% and 76.70% of the effect of NLR and MLR on PTB, respectively. When NLR, MLR, GNRI, and PNI were integrated with traditional clinical indexes, the AUC increased to 0.723 (95% CI: 0.668-0.777). Conclusion: Nutrition and inflammatory response are significantly associated with PTB severity, and nutritional status mediates the effect of inflammatory response on PTB severity.

1 March 2026 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
YXYu Xiao
Yu Xiao
PHPeng-Fei Huang
Peng-Fei Huang
LXLei Xie
Lei Xie
LGLei Gao
Lei Gao
YHYi Han
Yi Han
HWHua Wang
Hua Wang
Background: Contezolid (CZD), a novel oxazolidinone, is a promising therapeutic option for the treatment of Mycobacterium tuberculosis. However, clinical evidence of its safety and efficacy in managing drug-resistant tuberculosis (DR-TB) remains limited. Methods: A retrospective analysis was performed on 135 patients with DR-TB treated at Anhui Chest Hospital between January 2022 and September 2024, including 27 on CZD-based regimens and 108 on linezolid (LZD)-based regimens. Drug-related adverse events (AEs), including bone marrow suppression, peripheral neuropathy, optic neuritis, and gastrointestinal reactions, were systematically recorded. Therapeutic efficacy was comprehensively evaluated based on clinical symptoms, radiological findings, and microbiological results. The 12-month safety and efficacy of the two regimens in DR-TB were assessed. Results: The incidence of AEs in the LZD group reached 54.63%, significantly higher than the 3.7% observed in the CZD group (χ2 = 22.69, P < 0.001). Notably, the rates of bone marrow suppression and peripheral neuropathy in the LZD group were 22.22% and 27.78%, respectively, whereas no such AEs were reported in the CZD group (P = 0.004; P < 0.001, respectively). Regarding efficacy, CZD and LZD showed comparable outcomes in patients with DR-TB (P = 0.491). Conclusion: CZD may have clinical efficacy comparable to LZD in treating DR-TB, while appearing to offer an improved safety profile, notably in reducing bone marrow suppression and peripheral neuropathy.